Clinical Study
Diffuse Large B-Cell Lymphoma in Human T-Lymphotropic Virus Type 1 Carriers
Table 1
Clinical characteristics of 7 HTLV-1-positive patients with DLBCL.
| | Case | Sex | Age | WBC (×109/L) | ALC (×109/L) | Hb (g/dl) | Platelets (×109/L) | Stage | IPI score | Treatment | Response | Overall survival | Outcome |
| | (1) | M | 85 | 5.4 | 1.6 | 13.5 | 145 | I | 1 | CHOP | CR | 5 months | Dead | | (2) | F | 54 | 6.1 | 1.5 | 11.9 | 230 | II | 0 | CHOP | CR | 44 months | Alive | | (3) | M | 73 | 5.7 | 2.5 | 12.1 | 293 | II | 1 | R-CHOP | CR | 19 months | Alive | | (4) | M | 47 | 4.9 | 1.1 | 11 | 240 | IV | 3 | CHOP | PD | 8 months | Dead | | (5) | F | 45 | 6.2 | 0.9 | 10.5 | 200 | IV | 3 | R-CHOP | CR | 24 months | Alive | | (6) | F | 65 | 5.4 | 1.3 | 11.1 | 180 | III | 3 | CHOP | CR | 48 months | Alive | | (7) | F | 63 | 7.2 | 1.3 | 10 | 320 | IV | 4 | R-CHOP | CR | 21 months | Alive |
|
|
ALC: absolute lymphocyte count; Hb: hemoglobin; IPI: international prognostic index; M: male; F: female; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP: rituximab + CHOP; CR: complete response; PD: progressive disease; WBC: white blood cell count.
|
